GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OPKO Health Inc (NAS:OPK) » Definitions » Cash Flow from Financing
中文

OPKO Health (OPKO Health) Cash Flow from Financing : $-11.3 Mil (TTM As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is OPKO Health Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, OPKO Health paid $0.0 Mil more to buy back shares than it received from issuing new shares. It spent $3.8 Mil paying down its debt. It paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.0 Mil from paying cash dividends to shareholders. It received $0.0 Mil on other financial activities. In all, OPKO Health spent $3.8 Mil on financial activities for the three months ended in Dec. 2023.


OPKO Health Cash Flow from Financing Historical Data

The historical data trend for OPKO Health's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OPKO Health Cash Flow from Financing Chart

OPKO Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 175.25 -35.08 -10.35 22.97 -11.30

OPKO Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.14 -13.12 3.46 2.11 -3.75

OPKO Health Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

OPKO Health's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

OPKO Health's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OPKO Health  (NAS:OPK) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

OPKO Health's issuance of stock for the three months ended in Dec. 2023 was $0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

OPKO Health's repurchase of stock for the three months ended in Dec. 2023 was $0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

OPKO Health's net issuance of debt for the three months ended in Dec. 2023 was $-3.8 Mil. OPKO Health spent $3.8 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

OPKO Health's net issuance of preferred for the three months ended in Dec. 2023 was $0.0 Mil. OPKO Health paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

OPKO Health's cash flow for dividends for the three months ended in Dec. 2023 was $0.0 Mil. OPKO Health received $0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

OPKO Health's other financing for the three months ended in Dec. 2023 was $0.0 Mil. OPKO Health received $0.0 Mil on other financial activities.


OPKO Health Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of OPKO Health's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


OPKO Health (OPKO Health) Business Description

Traded in Other Exchanges
Address
4400 Biscayne Boulevard, Miami, FL, USA, 33137
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a speciality active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.
Executives
Frost Phillip Md Et Al 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Hsiao Jane Ph D director 4400 BISCAYNE BLVD, MIAMI FL 33137
Gary J. Nabel director, officer: Chief Innovation Officer C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Elias A. Zerhouni director, officer: Vice Chairman and President 2099 PENNSYLVANIA AVENUE, NW 12TH FLOOR, WASHINGTON DC 20006
John A Paganelli director, other: Chairman of the Board OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Alexis Borisy director C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 16TH FLOOR, CAMBRIDGE MA 02142
Jon R Cohen director, officer: SVP OPKO; Exec Chairman BRLI C/O OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Prem A Lachman director 4400 BISCAYNE BLVD., MIAMI FL 33137
Roger Md Medel director 1301 CONCORD TERRACE, SUNRISE FL 33323
Rulfo Fernando Hernandez officer: CAO, Treasurer C/O OPKO HEALTH INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Anthony J Japour director 19805 N. CREEK PARKWAY, BOTHELL WA 98011
Robert Scott Fishel director C/O OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Adam Logal officer: Exec.Dir .of Fin., CAO,Treas. OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137